Veloxa XL Chewable Tablets for Dogs Pack of 2

Veloxa XL Chewable Tablets for Dogs are beef flavoured worming tablets.  They are a broad spectrum treatment for mixed infections by the following roundworms and tapeworms in dogs and puppies:

• Ascarids: Toxocara canis, Toxascaris leonina (adult and late immature forms)
• Hookworms: Uncinaria stenocephala, Ancylostoma caninum (adults)
• Whipworms: Trichuris vulpis (adults)
• Tapeworms: Echinococcus spp., Taenia spp. and Dipylidium caninum (adult and immature forms).

Fleas serve as intermediate hosts for one common type of tapeworm - Dipylidium caninum. Tapeworm infestation is certain to reoccur unless control of the intermediate hosts such as fleas, mice, etc. is undertaken. Tapeworm infestation is unlikely in pups less than 6 weeks of age.

• Veloxa is recommended for use in dogs less than 17.5 kg bodyweight. 
• Veloxa XL is recommended for use in dogs over 17.5 kg bodyweight.

Do not use for treatment of dogs weighing less than 17.5 kg (i.e. <17.5 kg).

The chewable tablets can be given directly to the dog or disguised in food. No starvation is needed before or after treatment. Due to a lipid-coating of praziquantel and added flavour, the chewable tablets are taken by most dogs voluntarily.

Duration of treatment

A single dose shall be used. If there is a risk of re-infestation, the advice of a veterinarian should be sought regarding the need for and the frequency of repeat administration.

Do not use in animals with a known sensitivity to any of the active substances or the ingredients.

In the interests of good hygiene, wash hands immediately after administering the tablet either to the dog or into the dog’s food.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the doctor.

In very rare cases transient, mild gastrointestinal signs (e.g. vomiting) may occur.

Do not use simultaneously with piperazine as the anthelmintic effects of pyrantel and piperazine may be antagonised.

Concurrent use with other cholinergic compounds can lead to toxicity.

Plasma concentrations of praziquantel may be decreased by concomitant administration with drugs that increase the activity of cytochrome P-450 enzymes (e.g. dexamethasone, phenobarbital).

Overdose

The combination of praziquantel, pyrantel embonate and febantel is well tolerated in dogs. In safety studies, a single dose of 5 times the recommended dose or greater gave rise to occasional vomiting.

Use during pregnancy, lactation or lay

Teratogenic effects attributed to high doses of febantel have been reported in sheep and rats. No studies have been performed in dogs during early pregnancy. Use of the product during pregnancy should be in accordance with a benefit/risk assessment by the responsible veterinarian. It is recommended that the product is not used in dogs during the first 4 weeks of pregnancy. Do not exceed the stated dose when treating pregnant bitches.

The chewable tablets may be used during lactation.

Active substances: Febantel 525 mg, Pyrantel 175 mg (corresponding to Pyrantel embonate 504 mg), Praziquantel 175 mg.